Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1949778 | 1.00 | SIRT2 (0.59) | SIRT2CA12CA2CA9MAPT | |
| SCHEMBL11182598 | 0.90 | SIRT2 (0.59) | SIRT2CA12CA2CA9MAPT | |
| SCHEMBL11182613 | 0.90 | SIRT2 (0.59) | SIRT2CA12CA2CA9MAPT | |
| SCHEMBL12955765 | 0.87 | SIRT2 (0.56) | SIRT2CA12CA2CA9MAPT | |
| SCHEMBL1950957 | 0.87 | SIRT2 (0.56) | SIRT2CA12CA2CA9MAPT | |
| SCHEMBL1026037 | 0.87 | SIRT2 (0.56) | SIRT2CA12CA2CA9MAPT | |
| SCHEMBL1948736 | 0.86 | MAPT (0.58) | SIRT2CA12CA2CA9MAPT | |
| SCHEMBL1948735 | 0.86 | MAPT (0.58) | SIRT2CA12CA2CA9MAPT | |
| SCHEMBL11263405 | 0.81 | CA12 (0.53) | SIRT2CA12CA2CA9MAPT | |
| SCHEMBL11263401 | 0.81 | CA12 (0.53) | SIRT2CA12CA2CA9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160828-B2 | Group 8 transition metal catalysts and method for making same and process for use of same in metathesis reaction | GUANG MING INNOVATION COMPANY (WUHAN) (CN) | 2018-12-25 | — | — | US | disclosed |
| CN-107250142-A | 8th group 4 transition metal catalyst and preparation method thereof and its application in metathesis reaction | 光明创新（武汉）有限公司 | 2017-10-13 | — | — | CN | disclosed |
| US-20170145152-A1 | GROUP 8 TRANSITION METAL CATALYSTS AND METHOD FOR MAKING SAME AND PROCESS FOR USE OF SAME IN METATHESIS REACTION | GUANG MING INNOVATION COMPANY (WUHAN) (CN) | 2017-05-25 | — | — | US | disclosed |
| EP-3164409-A1 | GROUP 8 TRANSITION METAL CATALYSTS AND METHOD FOR MAKING SAME AND PROCESS FOR USE OF SAME IN METATHESIS REACTION | Guang Ming Innovation Company (Wuhan) (CN) | 2017-05-10 | — | — | EP | disclosed |
| EP-2151446-B1 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | RIMTEC CORP (JP) | 2016-04-13 | — | — | EP | disclosed |
| WO-2016000242-A1 | GROUP 8 TRANSITION METAL CATALYSTS AND METHOD FOR MAKING SAME AND PROCESS FOR USE OF SAME IN METATHESIS REACTION | GUANG MING INNOVATION COMPANY (WUHAN) (CN) | 2016-01-07 | — | — | WO | disclosed |
| EP-2151445-B1 | Process for the preparation of bidentate Schiff base ruthenium catalysts containing a salicylaldimine-type ligand | RIMTEC CORP (JP) | 2015-02-18 | — | — | EP | disclosed |
| US-8338613-B2 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | RIMTEC CORPORATION (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20110137043-A1 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | TELENE S.A.S. (FR) | 2011-06-09 | — | — | US | disclosed |
| US-20110065925-A1 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | TELENE S.A.S. (FR) | 2011-03-17 | — | — | US | disclosed |
| EP-2151446-A1 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | Telene SAS (FR) | 2010-02-10 | — | — | EP | disclosed |
| EP-2151445-A1 | Process for the preparation of bidentate Schiff base ruthenium cataysts containing a saliclyldimine-type ligand | Telene SAS (FR) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145152-A1 | GROUP 8 TRANSITION METAL CATALYSTS AND METHOD FOR MAKING SAME AND PROCESS FOR USE OF SAME IN METATHESIS REACTION | F8, COASY, FADS1 | SIRT2 2319/4885CA12 1877/4885CA2 1110/4885 |
| US-20110137043-A1 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | SPR, LIG4, SUCLA2 | SIRT2 135/4885CA12 1429/4885CA2 1434/4885 |
| US-10160828-B2 | Group 8 transition metal catalysts and method for making same and process for use of same in metathesis reaction | F8, COASY, FADS1 | SIRT2 2319/4885CA12 1877/4885CA2 1110/4885 |
| US-20110065925-A1 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | SPR, LIG4, SUCLA2 | SIRT2 135/4885CA12 1429/4885CA2 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.